MORE►
molecular science
David Halbert, founder, chairman, and CEO of Caris Life Sciences. [Photo: Caris]
North Texas’ Caris Life Sciences Gets FDA Approval for its ‘MI Cancer Seek’ Companion Diagnostic Test
by Lance Murray | Nov 6, 2024
Caris said MI Cancer Seek will be used as a companion diagnostic to identify cancer patients who may benefit from treatment with targeted therapies.
by Lance Murray |
Jun 1, 2023
Expanding a collaboration they announced in January, the two companies aim to drive "the future of cancer care" with the new platform, enabling novel insights for precision medicine, therapeutic development, and clinical trials management for academic and biopharma researchers.
MORE►
by Lance Murray |
Jan 23, 2023
Caris Life Sciences, the Irving-based biotech company, announced Thursday that it closed a senior secured term loan providing up to $400 million in capital from OrbiMed and Braidwell, bringing its funding total since 2018 to roughly $1.7 billion....
MORE►
by Lance Murray |
Dec 12, 2019
The Genomic Profiling Similarity Score uses over 6,500 mathematical models in a machine learning algorithm to compare molecular characteristics of a patient's tumor against Caris' extensive database.
MORE►
